'Table s1' diaporamas de présentation

Cross-Border Portfolio Investment Through CIVs

OECD Committee on Fiscal Affairs Roundtable on Collective Investment Vehicles February 1-2, 2006 -- Paris, France Selected Treaty Issues Affecting Collective Investment Vehicles Investing in Securities Stephen E. Shay, Ropes & Gray LLP. Cross-Border Portfolio Investment Through CIVs.

326 views • 18 slides

Figure S1

Figure S1. Figure S2. Table S1. Table S2. Table S3. Table S4.

100 views • 6 slides

(A)

Figure S1, Oladipo et al. (A). (B). Figure S2, Oladipo et al. Table S1, Oladipo et al. Comparison of CXC-chemokine biomarker expression in malignant and adjacent normal colorectal epithelium. Table S2, Oladipo Correlation between CXCR1, CXCR2 and CXCL1 expression within CRC tissue.

163 views • 4 slides

12520_2010_42_MOESM1_ESM

133 views • 4 slides

Input IgG a -LSD1 a -HDAC1

Figure S1 Huang, Yi et al. Input IgG a -LSD1 a -HDAC1. Input IgG a -LSD1 a -HDAC1. Untreated. SAHA. IP:. (IB). LSD1. (IB). HDAC1. Figure S1. Figure S2 Huang, Yi et al. Untreated 1 m M 5 m M 10 m M H 2 O. A. SAHA. LSD1 Actin. Untreated 1 m M 5 m M 10 m M. B.

125 views • 3 slides

Table S1. GSEA of canonical pathway gene sets (CP) from MSigDB

Table S1. GSEA of canonical pathway gene sets (CP) from MSigDB. Enriched in QHii066-treated cells. Enriched in DMSO-treated cells. Table S2. GSEA of chemical and genetic perturbation signatures (CGP) from MSigDB. Enriched in QHii066-treated cells. Enriched in DMSO-treated cells.

170 views • 2 slides

Table S1. Efficiency of detergents in solubilization of recombinant CB 2 from E. coli membranes

Table S1. Efficiency of detergents in solubilization of recombinant CB 2 from E. coli membranes.

114 views • 1 slides

Table S1 . Hexose yield (% cellulose) released from enzymatic hydrolysis after pretreatment

Table S1 . Hexose yield (% cellulose) released from enzymatic hydrolysis after pretreatment. & , ( H) or (L) Indicated the sample in the pair with relatively high (H) or low (L) biomass digestibility; @ , Ratio of two sample values at pair.

97 views • 1 slides

Additional file 2: Table S1

Additional file 2: Table S1. Donor. Additional file 1:Table S1

69 views • 1 slides

Table S1: Base parameter values

Table S1: Base parameter values.

73 views • 1 slides

Table S1

Table S1.

104 views • 1 slides

Additional file 2: Table S1

Additional file 2: Table S1. Donor. Additional file 1:Table S1

57 views • 1 slides

Table S1

Table S1. Table S1. The primer list used in the present study.

119 views • 1 slides

Supplemental Table S1. Patient characteristics (n=101)

Supplemental Table S1. Patient characteristics (n=101).

95 views • 1 slides

Table S1. Mutational status of pancreatic cell lines used.

Table S1. Mutational status of pancreatic cell lines used.

87 views • 1 slides

Table S1. List of antibodies

Table S1. List of antibodies. Dupuy et al ., 2013.

95 views • 1 slides

Table S1. Composition of Kal-1

Table S1. Composition of Kal-1.

102 views • 1 slides

TABLE S1

TABLE S1.

78 views • 1 slides

Tumor diameter

123 views • 1 slides

Table S1. Functional gene grouping.

Table S1. Functional gene grouping. APOPTOSIS : ABL, BRCA1, CIDIA, GADD45 ? , GADD45 ? , GML, IP6K3, PCBP4, AIFM1 (PDCD8), PPP1R15A, RAD21, p53, p73. CELL CYCLE ARREST : CHK1, CHK2, DDIT3 (CHOP), GADD45 ? , GML, GTSE1, HUS1, MAP2K6, MAPK12, PCBP4, PPP1R15A, RAD17, RAD9A, SESN1, ZAK.

101 views • 1 slides